Why Trump’s diesel deal offers little relief from the oil squeeze
Renewed attacks in the Strait of Hormuz and record-high shipping costs continue to pressure the oil market, despite a recovery in exports from the Middle East.
LGP
Pharmaceuticals, Biotechnology & Life Sciences
Little Green Pharma
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 10 Feb 2025
- Reported shorts
- 961
- Shares on issue
- 302.873M
Little Green Pharma (LGP) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineEarn Only a Little From Work? Will You Get the Full New Standard Deduction?
Highlights The new standard work deduction is capped at your assessable labour income. Students, sole traders, asset holders and non-residents could receive a smaller amount or none. The ATO's eligibility rules exclude several broad groups entirely. The new standard deduction for work-related expenses won't be worth a significant amount to everyone. People whose only income comes from dividends or a business get nothing at all. That matters for casual workers, sole traders and asset holders w...
Google NewsCould TGA Closed-Loop Reforms Hit Little Green Pharma (ASX:LGP)? - Kalkine Media
Could TGA Closed-Loop Reforms Hit Little Green Pharma (ASX:LGP)? Kalkine Media
ASX
What Could Little Green Pharma Ltd (ASX:LGP) Bring to the Cannabis Stocks Spotlight as Product Expansion Evolves?
Highlights A softer global equity tone is likely to increase attention on relative resilience across ASX sectors. Little Green Pharma Ltd is assessed through the current cannabis shares backdrop rather than a directional share-price call. Operational adaptability and regulatory execution and commercial discipline are the main themes to monitor. The ASX is confronting a more volatile cross-asset backdrop as higher yields and energy prices challenge sentiment. That makes Little Green Pharma Ltd...
What Does Little Green Pharma (ASX:LGP) Mean?
Highlights Little Green Pharma (ASX:LGP) cultivates and manufactures medicinal cannabis products in Australia. The company supplies domestic patients while pursuing select international opportunities. Regulatory settings continue to shape the broader outlook for Cannabis Stocks. Australia's medicinal cannabis sector continues to evolve within a tightly regulated framework, and Little Green Pharma (ASX:LGP) remains one of the more recognisable names within that space. As a domestic cultivator ...
What Does Little Green Pharma (ASX:LGP) Mean for Cannabis Stocks? - Kalkine Media
What Does Little Green Pharma (ASX:LGP) Mean for Cannabis Stocks? Kalkine Media
What Is Little Green Pharma (ASX:LGP) Signalling Now?
Highlights Little Green Pharma (ASX:LGP) cultivates and manufactures medicinal cannabis products in Australia. The company supplies domestic patients while pursuing select international opportunities. Regulatory settings continue to shape the broader outlook for Cannabis Stocks. Australia's medicinal cannabis sector continues to evolve within a tightly regulated framework, and Little Green Pharma (ASX:LGP) remains one of the more recognisable names within that space. As a domestic cultivator ...
Why Did Little Green Pharma (ASX:LGP) Merge With Cannatrek?
Highlights The medicinal cannabis producer completed a scheme of arrangement that folded a domestic rival into the combined group. [ASX 300] Cannatrek security owners emerged with the larger share of the enlarged register, with contingent securities attached to how certain liabilities resolve. Fresh securities were quoted mid-year as the combined operation moved through its integration phase. Little Green Pharma, the Western Australian medicinal cannabis producer that trades as (ASX:LGP), has...
Why Is Little Green Pharma (ASX:LGP) Leaning on Europe?
Highlights European and United Kingdom sales moved ahead of the Australian revenue base. A court-approved scheme folded Victorian producer Cannatrek into the group. Australian regulators are examining reform of the medicinal cannabis access pathway. Little Green Pharma (ASX:LGP) has spent the year reshaping itself around twin pillars: a completed merger with Victorian producer Cannatrek, and a European sales base that has moved past its Australian revenue for the first time. The medicinal can...
Little Green Pharma (ASX:LGP): How is LGP integrating Cannatrek?
Highlights Little Green Pharma has a fresh disclosure linked to integration, branded access and export market execution. The Australian and European medicinal cannabis platform remain central to the operating assessment. Execution, cash discipline and disclosure continuity remain the clearest markers. [All Ordinaries] Little Green Pharma (ASX:LGP) is back in focus after recent corporate reporting followed the completed combination with Cannatrek. The timely update directs attention to the Aus...
Why Is Little Green Pharma (ASX:LGP) in Focus Among Cannabis Stocks?
Highlights Little Green Pharma confirmed a new group finance appointment shortly after its annual general meeting concluded The appointment follows a quarterly activities report lodged earlier in the reporting cycle The producer continues to position itself as a vertically integrated operator across the local cannabis category Little Green Pharma Limited (ASX:LGP) has confirmed the appointment of a new group finance lead, landing shortly after the company held its annual general meeting amid ...
Why Is Little Green Pharma (ASX:LGP) Shaping Cannabis Stocks?
Highlights Little Green Pharma has built its story on exporting Australian grown medicinal cannabis into European markets. Revenue has expanded steadily while much of the local sector has struggled to commercialise at all. Regulatory settings at home continue to shape how quickly domestic demand can grow. Australian market attention has shifted toward Little Green Pharma (ASX:LGP) as company-specific developments add a fresh layer to the cannabis stocks conversation. Little Green Pharma (ASX:...
Could Little Green Pharma (ASX:LGP) Shift Cannabis Focus?
Highlights Little Green Pharma is drawing attention as medicinal cannabis commercial execution becomes more important to the Australian market conversation. The companys position across cultivation, manufacturing and distribution capabilities serving Australia and European markets gives readers a practical lens on changing conditions in medicinal cannabis. Operational delivery, capital discipline and clear strategic priorities remain central as the sector continues evolving. Australias sharem...
Can Little Green Pharma (ASX:LGP) Reset the Cannabis Narrative?
Highlights The cultivator's annual accounts showed revenue easing and a return to a loss position after a difficult trading year. An agreed merger with a privately owned domestic peer, structured as a reverse takeover, has dominated the corporate agenda. European demand, particularly across German-speaking markets, is the strategic rationale behind the combination. For Little Green Pharma (ASX:LGP), sector conditions and company execution are intersecting at the same time. Medicinal-cannabis ...
What Could Little Green Pharma (ASX:LGP) Change Next?
Highlights Little Green Pharma has appointed a new Group Chief Financial Officer as the combined business moves deeper into post-merger integration. The finance leadership change arrives while the group is aligning medicinal cannabis operations across Australia and Europe. Execution around integration, operating discipline and international scale is likely to shape how the next phase of the company story develops. Leadership changes can look routine on the surface, but timing can make them st...
Little Green Pharma (ASX:LGP) Sector Pulse: What Could Shape the Next Move on 19 August
Highlights Healthcare was the standout sector on 18 August: CSL rose sharply after its FY26 result, while Cochlear and Pro Medicus also drew strong market reactions. Little Green Pharma (ASX:LGP) is the primary company lens, while Incannex Healthcare (ASX:IHL), ECS Botanics (ASX:ECS), Cann Group (ASX:CAN) provide category context. The article focuses on regulatory execution, funding needs and commercial traction without using directional investment recommendations. The central question for ca...
Little Green Pharma (ASX:LGP) Cash Flow Check: What Investors Need to Watch on 19 August
Highlights BHP reported FY26 results on 18 August, with copper overtaking iron ore as its largest earnings contributor and the company highlighting strong cash generation. Little Green Pharma (ASX:LGP) is the primary company lens, while Renascor Resources (ASX:RNU), BrainChip Holdings (ASX:BRN), Cann Group (ASX:CAN) provide category context. The article focuses on funding discipline, liquidity and milestone quality in lower-priced shares without using directional investment recommendations. L...
Darts club membership booms as miners create 'great little community'
The previous darts club, about 200 kilometres north-east of Mackay, closed a few years ago, but the dedication and perseverance of a few members has brought it back to life.
Why Little Green Pharma (ASX:LGP) Matters in Cannabis?
Highlights Little Green Pharma is viewed through patient demand, product mix and distribution reach, keeping the discussion anchored to company-specific operating evidence. The Cannabis Stocks lens is used only as context; the article separates Little Green Pharma's business model from broader sector shorthand. Fresh disclosures around regulatory execution, cultivation efficiency and commercial scale are the most useful checkpoints for judging how the narrative is evolving. Australian equitie...
Little Green Pharma (ASX:LGP) Lifts on Export Push
Highlights European shipments remain the defining commercial thread for the Western Australian producer. Manufacturing certification across two jurisdictions underpins access to regulated markets. Domestic price competition continues to compress margins across the local supply base. Little Green Pharma (ASX:LGP), the Western Australian cultivator and manufacturer of regulated medicinal cannabis products and operator of a Danish production facility, has edged higher on the local market as Euro...
Little Green Pharma (ASX:LGP) Medicinal Cannabis Market: Market Outlook
Highlights Domestic medicinal cannabis market maturing with increasing patient access Pharmaceutical distribution channels opening for cannabis-derived medicines Manufacturing quality standards creating competitive differentiation Little Green Pharma (ASX:LGP) establishes market positioning within Australia's evolving medicinal cannabis landscape. The company builds domestic patient access while pharmaceutical distribution channels expand. The broader market context can also be viewed throu...
Why Is Little Green Pharma (ASX:LGP) Drawing Fresh Attention?
Highlights Little Green Pharma is in focus after a fresh company disclosure added new context to the public record. The cannabis stocks lens centres on regulated market access, product mix, distribution reach and cash discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures especially impor...
Little Green Pharma (ASX:LGP): Cannabis Consumer Products Trends to Watch
Highlights Consumer cannabis product formats diversify beyond traditional flowers Brand development drives consumer loyalty and market segmentation Edibles, beverages, and wellness products expand market categories Cannabis consumer product markets are maturing beyond traditional flower formats into diverse product categories including edibles, beverages, topical preparations, and wellness products. The broader [ASX 200] remains an important benchmark for Australian market sentiment. Market d...
Little Green Pharma (ASX:LGP): Medical Cannabis Expansion Trends to Watch
Highlights Medical cannabis regulatory frameworks liberalize across jurisdictions Therapeutic applications expand beyond traditional use cases Clinical research validates cannabis derivatives for medical conditions The medical cannabis sector has undergone significant transformation as regulatory frameworks worldwide liberalize and clinical evidence supporting therapeutic applications accumulates. The broader [ASX 200] remains an important benchmark for Australian market sentiment. Little Gre...
Why Little Green Pharma (ASX:LGP) Is Shaping Cannabis Stocks Today
Highlights Little Green Pharma (ASX:LGP) provides a timely company lens as the ASX digests reporting-season news and a weaker banking sector. Cann Group (ASX:CAN) shows why company economics matter more than a broad Cannabis stocks label. The next RBA decision, company guidance and cash-generation evidence remain key confirmation points for Cannabis stocks. Australian equities entered the new week with a record-level backdrop but a more selective tone. The session also reinforced the importan...
What Little Green Pharma (ASX:LGP) And Cann Group (ASX:CAN) Reveal About Cannabis Stock
Highlights Little Green Pharma (ASX:LGP) provides a timely company lens as the ASX digests reporting-season news and a weaker banking sector. Cann Group (ASX:CAN) shows why company economics matter more than a broad Cannabis stocks label. The next RBA decision, company guidance and cash-generation evidence remain key confirmation points for Cannabis stocks. Australian equities entered the new week with a record-level backdrop but a more selective tone. The session also reinforced the importan...
Why Is Little Green Pharma (ASX:LGP) Drawing Fresh Market Attention?
Highlights Little Green Pharma is attracting attention as commercial execution becomes a key focus for the market. Australian Penny Stocks continue facing close scrutiny around cash management, operating discipline and business expansion. The company is being assessed on whether financial flexibility can support long-term execution in a changing operating environment. Australian shares continue navigating a period where company-specific developments are taking centre stage as broader economic ...
Little Green Pharma moves into focus as medical-cannabis expense
Highlights Little Green Pharma is drawing attention today around medical-cannabis expansion. The update gives the sector a fresh company-specific news hook. Execution and wider market conditions remain central to the next read-through. Little Green Pharma (ASX:LGP) is in focus today as the Australian market weighs medical-cannabis expansion, putting the companys latest operational narrative at the centre of a busy local trading session. Why the update matters now The immediate reaction matter...
Why Little Green Pharma and Cannatrek Merger Creates Vertically Integrated Cannabis Superpower Is in Focus (ASX:LGP)?
Highlights Little Green Pharma (ASX:LGP), Perth-based Little Green Pharma (ASX:LGP) remains in focus as medical cannabis development and operational delivery continue shaping sector attention. Within the [ASX 300], attention is also extending to ASX Cannabis Stocks as companies balance operational delivery, sector demand and disciplined capital management. Patient access, regulation and product quality remain central considerations as Australian companies respond to evolving market conditions. ...
ASX Penny Stocks: Why Is Little Green Pharma (ASX:LGP) Reporting Season in Focus?
Highlights Little Green Pharma enters the reporting period with cash runway and sales conversion central to the next company disclosure and the wider market debate. The Penny Stocks backdrop is testing liquidity, milestones and balance-sheet runway as rates, demand and capital discipline shape market interpretation. A comparison with Cann Group clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. The domestic share market begins the current ...
Little Green Pharma (ASX:LGP): What Puts Cash Flow in Focus?
Highlights Little Green Pharma enters the reporting period with sales mix and cash generation central to the next company disclosure and the wider market debate. The Cannabis Stocks backdrop is testing regulation, cash runway and product economics as rates, demand and capital discipline shape market interpretation. A comparison with ECS Botanics clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. Australia's listed market approaches the cur...
Why Is the Market Watching Little Green Pharma (ASX:LGP)?
Highlights Little Green Pharma finalises its merger with Cannatrek, forming a broader medicinal cannabis group with an expanded product range. Combined revenue climbs sharply as flower and oil demand strengthens across the merged patient and pharmacy network. The enlarged group applies for fresh ASX share quotation as it works to integrate manufacturing, cultivation and distribution operations. Little Green Pharma (ASX:LGP), the West Australian medicinal cannabis cultivator and manufacturer, ...
StockheadOra Banda expands Little Gem gold footprint as Sapphire lodes grow
Little Gem is close to the company’s Riverina underground mine and Davyhurst processing hub in WA’s Eastern Goldfields, giving the ... Read More The post Ora Banda expands Little Gem gold footprint as Sapphire lodes grow appeared first on Stockhead.
Is Little Green Pharma (ASX:LGP) Back In Cannabis Focus?
Little Green Pharma is being read through export demand and cash discipline as cannabis stocks regain attention The latest ASX mood blends local inflation relief with offshore caution ECS Botanics adds a peer reference that keeps the category story grounded Large miners stayed central after Rio's latest profit and dividend update refreshed the resources conversation, leaving Little Green Pharma in a sharper editorial frame for Australian market readers. ECS Botanics (ASX:ECS), medicinal cannabi...
Why Is Little Green (ASX:LGP) Back on the Cannabis Stocks Radar?
Highlights Little Green sits inside a sharper regulated cannabis debate after thin sector news pushing attention back to balance sheets and product channels. Little Greens position in the oil cooling trade inside Cannabis Stocks rewards cleaner balance sheets, steadier revenue and credible execution. Cannabis Stocks around Little Green remain tied to local rates, offshore leads and company-specific operating evidence. The Australian share market moved into today's session with a cleaner risk ...
Chargrill Charlie’s is the little chook shop that could. It’s just not so little any more
The suburban roast chicken and takeaway joint, backed by Big Chicken and private equity, is one of many chains jostling for supremacy in the chicken wars.
Why Is (ASX:LGP) Reshaping Australia's Cannabis Growth Story?
Highlights Expanding patient access is supporting the steady development of Australia's medicinal cannabis market. Regulatory pathways continue to determine how companies bring products to patients. The sector is increasingly rewarding businesses generating commercial revenue rather than relying on market optimism. Australia's medicinal cannabis industry has entered a more mature phase as patient demand continues expanding through regulated healthcare channels. Little Green Pharma (ASX:LG...
LGP: Why Is Execution The Smallcap Test?
Highlights Little Green Pharma is being assessed through export discipline as the ASX market turns more selective. Smallcap Stocks attention is tied to renewed scrutiny on specialised healthcare exporters and the wider reporting-season mood. The key debate is whether supply reliability can support steadier confidence without relying on hype. The Australian share market has moved into a more selective phase, and Little Green Pharma (ASX:LGP) is drawing attention because a medicinal cannabis prod...
Can Little Green Pharma (ASX:LGP) Turn Record Sales Into Momentum?
Highlights The medicinal cannabis producer posted its strongest quarter of sales yet. Export demand and a broadening product range underpinned the growth. A sector peer sharpened its focus by shedding an overseas clinic arm. A West Australian medicinal cannabis producer lit up the sector after reporting its strongest quarter of sales on record, a rare bright spot in a category better known for volatility than momentum. Little Green Pharma (ASX:LGP), which cultivates and manufactures medicinal...
Why Is Little Green Pharma (ASX:LGP) Drawing Fresh ASX Attention?
Highlights Little Green Pharma is gaining attention as export access and operational execution become key themes across the Australian market. The focus has shifted towards market access, cash generation and disciplined delivery rather than broad sector optimism. A selective market backdrop is encouraging closer scrutiny of business fundamentals across the medicinal cannabis industry. Little Green Pharma has entered the spotlight as Australian markets increasingly prioritise export capabi...
Why Is Little Green Pharma (ASX:LGP) Quoting Additional Shares on the ASX?
Highlights Little Green Pharma has applied for the quotation of additional ordinary shares on the ASX. The new securities were issued following the exercise or conversion of existing equity-linked instruments. The quotation expands the company's listed share base and supports its ongoing capital management strategy. Little Green Pharma (ASX:LGP) has applied to the Australian Securities Exchange for the quotation of additional ordinary fully paid shares following the exercise or conversion of ex...
Can Little Green Pharma’s LGP Prove the Cannabis Reset?
Highlights Little Green Pharma (ASX:LGP) is drawing attention as regulated exports and product quality become central to its commercial credibility. Cash discipline, distribution reach and compliance remain more important than broad enthusiasm surrounding medicinal cannabis. Readers following Cannabis Stocks are looking for repeatable revenue, controlled spending and clear execution. Little Green Pharma faces a cannabis reset as regulated exports, product quality, distribution strength, c...
Little Green Pharma (ASX:LGP) Pushes Deeper Into European Markets
Highlights Export demand from Europe is emerging as the clearest revenue diversifier for Australian cannabis producers. Germany's reformed access framework has expanded the addressable market for compliant suppliers. Domestic pricing pressure is making offshore channels commercially essential rather than optional. Little Green Pharma (ASX:LGP), the Western Australian producer that became the first Australian company to export locally grown medicinal cannabis to Europe, sits at the centre of a q...
Little Green Pharma (ASX:LGP) Posts Record Revenue as Cannabis Doubts Fade
Highlights Little Green Pharma closed its financial year with record revenue, growing at a mid-teens pace on the year before. The market is increasingly separating cannabis companies with audited sales from those still trading on stories and pipelines. Production facilities in Western Australia and Denmark give the group a rare two-hemisphere platform serving both local and European patients. Little Green Pharma (ASX:LGP), the Western Australian medicinal cannabis producer with cultivation and ...
Top Cannabis Stocks to Watch: Little Green Pharma (ASX:LGP) Faces the Consolidation Challenge
Highlights Little Green Pharma is drawing attention as the medicinal cannabis sector shifts towards operational scale and execution. The market is increasingly rewarding companies with stronger cash flow discipline and regulated market access. Sector sentiment is moving beyond growth narratives towards sustainable business performance. Little Green Pharma (ASX:LGP) has emerged as a closely watched name as Australia's medicinal cannabis ...
Little Green Pharma Leans on Europe as Cannabis Exports Grow
Highlights Little Green Pharma continues to build on its position as an early Australian exporter of locally grown medicinal cannabis to Europe. The company has reported meaningful revenue alongside positive adjusted earnings, a rarity in the sector. Export frameworks and pharmacy channels are becoming the industry's route to sustainable growth. Little Green Pharma (ASX:LGP), the Western Australian producer that became the first homegrown grower to export locally cult...
What Makes Little Green Pharma (ASX:LGP) Stand Out in Cannabis Stocks?
Highlights Little Green Pharma is drawing attention as medicinal cannabis businesses face greater focus on operational execution. Export demand, product mix and operating efficiency are shaping how the sector is being assessed. Market attention is shifting from sector themes toward financial discipline and sustainable business performance. Australia's sharemarket continues to navigate a cautious environment as sector leadership shifts across ...
Why Is LGP Facing a Bigger Cannabis Test Than the Market Expects?
Highlights Little Green Pharma is drawing attention as export execution becomes more important than short-term market enthusiasm. Operational discipline and production quality are emerging as the key themes shaping the company's market narrative. Broader ASX sentiment is encouraging closer scrutiny of medicinal cannabis businesses amid a cautious sector backdrop. Little Green Pharma is drawing market attention as export capability, producti...
Why Is LGP Back on the Radar as Penny Stocks Face Fresh Pressure?
Highlights Little Green Pharma is attracting attention through export expansion and production discipline rather than short-term market momentum. Operational execution and balance sheet clarity remain key themes for smaller listed companies. Penny Stocks continue to face selective market sentiment as investors favour businesses demonstrating measurable progress. Australia's share market opened with a cautious tone as higher oil prices linke...
Top Little Green Pharma (ASX:LGP) Signals That Could Reshape Cannabis Stocks
Highlights Little Green Pharma (ASX:LGP) remains in focus as medicinal cannabis businesses face a more selective Australian market environment. Market attention has shifted towards offshore distribution, disciplined cost management and operational execution across ASX Cannabis Stocks. Botanix Pharmaceuticals (ASX:BOT) and ECS Botanics (ASX:ECS) provide useful context as regulated healthcare companies operating across different cannabis-related segments. The Austral...
Letter to Shareholders regarding Annual General Meeting
other announcement